Lisata Therapeutics, Inc. (LSTA) stock forecast & analysis
1 analysis. Latest: .
New accounts start with 200 free tokens.
Market Scanner’s AI analysis of Lisata Therapeutics, Inc. (LSTA), updated August 2026: Lisata Therapeutics' clinical-stage focus contrasted with negative technicals and strong buying pressure signals
Summary
Lisata Therapeutics' clinical-stage focus contrasted with negative technicals and strong buying pressure signals
Recent analyses for Lisata Therapeutics (LSTA) covered its financial performance as a clinical-stage biopharmaceutical company, noting net losses and minimal revenues in recent fiscal periods. The company's balance sheet indicated healthy liquidity with no reported debt. Technical analyses highlighted a significant downtrend with prices well below key moving averages, though a high Money Flow Index suggested strong buying pressure.
LSTA news & sentiment
News reports indicated a generally positive trend in private credit and loan markets, with specific funds outperforming benchmarks. However, there was an absence of direct news or significant mentions for LSTA itself within the provided headlines, while broader market concerns about US national debt and cybersecurity breaches were noted.
LSTA technical picture
LSTA's price action showed a strong downtrend, trading significantly below its 50-day and 200-day simple moving averages. Short-term momentum was negative, though the current price was above the 10-day exponential moving average. Relative Strength Index readings were neutral, while the Money Flow Index indicated strong buying pressure, potentially signaling a reversal.
Fundamentals
Lisata Therapeutics reported minimal revenues and net losses in recent fiscal periods, alongside operating losses. The company's balance sheet showed healthy liquidity with no reported debt, and strong current and quick ratios.
Factors discussed — upside
- No reported total debt
- Strong liquidity with high current and quick ratios
- High Money Flow Index (MFI) indicating strong buying pressure
Factors discussed — risks
- Significant downtrend with prices below 50-day and 200-day SMAs
- Net losses and minimal revenues reported
- Current price above 10-day EMA but overall short-term momentum negative
- Financial performance
- Technical indicators
- Liquidity and debt
Summary updated .
Analyses
Recent LSTA.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Lisata Therapeutics, Inc.?
- The company has no reported total debt and exhibits strong liquidity with high current and quick ratios. Additionally, a high Money Flow Index suggests significant buying pressure in the stock.
- What are the risks for Lisata Therapeutics, Inc.?
- The stock is in a significant downtrend, trading below key moving averages, and short-term momentum appears negative. Recent financial reports indicate net losses and minimal revenues, contrasting with the strong buying pressure signals.
- Is Lisata Therapeutics, Inc. bullish or bearish?
- Recent AI analyses of Lisata Therapeutics, Inc. examined factors on both sides. Discussed upside: The company has no reported total debt and exhibits strong liquidity with high current and quick ratios. Additionally, a high Money Flow Index suggests significant buying pressure in the stock. Discussed risks: The stock is in a significant downtrend, trading below key moving averages, and short-term momentum appears negative. Recent financial reports indicate net losses and minimal revenues, contrasting with the strong buying pressure signals. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Lisata Therapeutics, Inc.?
- News reports indicated a generally positive trend in private credit and loan markets, with specific funds outperforming benchmarks. However, there was an absence of direct news or significant mentions for LSTA itself within the provided headlines, while broader market concerns about US national debt and cybersecurity breaches were noted.
- Bundles used
- gemini-low-v2
Run a fresh LSTA.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.
Or sign in to read every LSTA.US report already in the library